Quest Diagnostics Insider Sold Shares Worth $5.48 Million
A recent SEC filing indicates that an insider at Quest Diagnostics Incorporated sold company shares valued at approximately $5.48 million.
Stocks · News reference
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Metalla Royalty & Streaming Ltd. Schedule 13D/A Filing
Tether Global Investments Fund, S.I.C.A.F., S.A. filed an amended Schedule 13D regarding its position in Metalla Royalty & Streaming Ltd.
HSBC Upgrades Labcorp to Buy From Hold
HSBC has upgraded its rating for Labcorp from Hold to Buy, setting a price target of $40.
Mizuho Securities Adjusts Labcorp Price Target
Mizuho Securities has updated its price target for Labcorp Holdings Inc. to $400 from $355.
Incyte Discloses $246 Million Benefit from CMS Litigation Settlement
Incyte's net sales guidance for Opzelura includes a one-time $246 million financial benefit resulting from a settlement with the Centers for Medicare and Medicaid Services (CMS).
Leerink Partners Adjusts Incyte Price Target
Leerink Partners has revised its price target for Incyte Corporation from $154 to $150.